Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib / II Open-Label Stduy of APG-2575 Monotherapy or in Combination With Lenalidomide / Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04674514 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT04674514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04674514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib / II Open-Label Stduy of APG-2575 Monotherapy or in Combination With Lenalidomide / Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 13, 2021
Completion date
May 31, 2024
Enrollment
48 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma